Synthetic Genomics Exec Joins Agenovir as Chief Scientific Officer

Bolyn Hubby is joining antiviral drug developer Agenovir to become the company’s chief scientific officer. Hubby comes to South San Francisco-based Agenovir from Synthetic Genomics, where she was vice president of vaccines and antimicrobials research and development. Her experience also includes posts at Liquidia Technologies and AlphaVax. Last year, Agenovir raised $10.6 million to apply the CRISPR gene-editing technology to its drug research.

Author: Frank Vinluan

Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times.